Subscription Center
May 22, 2009 | 5
Drug companies need little arm-twisting when it comes to investing their resources into diseases that afflict millions. But what about a disease that affects only a few thousand people?
To stimulate drug development for diseases with few paying customers – whether due to its sheer rarity or its sufferers’ poverty – the National Institutes of Health (NIH) has committed $120 million over five years to a new program called Therapeutics for Rare and Neglected Disease (TRND). The new trans-NIH program aims to support researchers with more money for in-house NIH studies and additional funds for external academic, advocacy and foundation collaborations.
See what we're tweeting about
sciammind #SciAmBlogs Wednesday - niche construction, cicadas, ageing, Moon, pirates' dodo, sick caecilians, hurricane f... http://t.co/sVtkJrmrg2
JenLucPiquant Packed house for @seanmcarroll's public lecture at UC Davis. And great Q's from engaged audience. #herocks
FlyingTrilobite .@pegspirate Please excuse me while I make some graven images, as is my trade. #popelovesatheists
Deadline: Jul 25 2013
Reward: Varies
This challenge provides an opportunity for Solvers to build a web-based or mobile “app” to explore data relationships in scholarly conte
Deadline: Jun 30 2013
Reward: $1,000,000 USD
This is a Reduction-to-Practice Challenge that requires written documentation and&
Powered By: 
YES! Send me a free issue of Scientific American with no obligation to continue the subscription. If I like it, I will be billed for the one-year subscription.
